Squamous cell carcinoma of liver and intrahepatic biliary tract Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

1 event

Mar 2006

Erbitux: FDA approved

For use in combination with radiation therapy, for the treatment of locally or regionally advanced squamous cell carcinoma of the head and neck (SCCHN) and for use as a single agent for the treatment of patients with recurrent or metastatic SCCHN for whom prior platinum-based therapy has failed

FDAcompleted

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Squamous cell carcinoma of liver and intrahepatic biliary tract.
Check the disease page for updates →

Approved Treatments

1 FDA-approved

Erbitux

(cetuximab)Orphan drug

ImClone Systems Incorporated

Epidermal Growth Factor Receptor Antagonist [EPC]

12.1 Mechanism of Action The epidermal growth factor receptor (EGFR, HER1, c-ErbB-1) is a transmembrane glycoprotein that is a member of a subfamily o...

Approved Mar 2006FDA label ↗

View full treatment details on disease page →